Navigation Links
Protein Sciences Announces Termination of Deal to Sell to Emergent BioSolutions
Date:7/29/2008

- PSC terminates sale due to Emergent's breaches

- PSC BLA for FluBlok remains on track with the FDA

- PSC awaiting decision on BARDA contract award

MERIDEN, Conn., July 29 /PRNewswire/ -- Protein Sciences Corporation ("PSC") announced today that the sale of its business under an Asset Purchase Agreement between PSC and Emergent BioSolutions, Inc. (NYSE: EBS) and its affiliate (collectively "Emergent") has been terminated by PSC due to breaches by Emergent. PSC cited multiple breaches by Emergent including disclosure and mischaracterization of PSC's material confidential information obtained from PSC during due diligence and Emergent's failure to fulfill its obligation to provide adequate funding to PSC.

Daniel D. Adams, President and CEO, said, "Emergent's blatant disregard for its contractual commitments is shocking. They continue to try to damage PSC with inappropriate and unauthorized contact to our customers and collaborators and appear to have launched an effort to disrupt the approval process for our BLA for FluBlok(R). Fortunately, we have loyal customers, collaborators and shareholders that remain very supportive of PSC and our management team."

In other developments, PSC announced that the FDA's inspection of PSC's facility and operations in connection with its Biologics License Application (BLA) for FluBlok was completed in mid-July. Manon Cox, PSC's Chief Operating Officer, noted, "We were well prepared for the FDA inspection of our manufacturing facility and are satisfied with the nature of the preliminary comments that we received from the FDA. We remain on track for a decision on our BLA by mid-October, 2008 under the FDA's accelerated approval pathway." PSC also announced that it reached an important milestone related to FluBlok when it successfully produced the vaccine necessary to combat each of the three strains that will make up the influenza vaccine for the 2008-2009 flu season.

PSC also announced that it submitted a proposal for federal funding for a contract to develop recombinant seasonal and pandemic influenza vaccines from the Department of Health and Human Services (BARDA). Negotiations over the contract have been ongoing and a decision may be reached by BARDA within the next few weeks. PSC has requested funding for, among other things, additional clinical trials to support pediatric and pandemic formulations of FluBlok; purchase of equipment for large scale manufacturing; and process and manufacturing facility validation as specified in the Request for Proposal issued by BARDA in 2007. If the contract is awarded, PSC expects that the work and funding will be spread over a five-year period.

About PSC. PSC is a privately held biotechnology company that uses proprietary recombinant DNA technology to manufacture human and animal vaccines, therapeutics and diagnostics. Our lead product is a human seasonal flu vaccine -- FluBlok(R). Our underlying technology is a viable alternative production platform to the egg-based production methods that currently dominate vaccine production and our 2007 revenues were in excess of $6,000,000, primarily from our GeneXpress and research antigen business.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
4. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
7. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
8. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
11. Immune system protein starves staph bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the topic will ... place May 15-18, 2017 in Los Angeles, Calif. Hosted by the Workgroup for ...
(Date:4/25/2017)... ... 25, 2017 , ... As part of the Stago EdVantage Virtual University ... for DIC in order to illuminate this clinical problem for people unfamiliar with the ... resulting in a high degree of morbidity and mortality. DIC is a confusing disorder ...
(Date:4/25/2017)... San Diego, CA (PRWEB) , ... April 25, ... ... (CRO) division of L3 Healthcare, is pleased to announce the company is now ... data management. The iMedNet software certification enables the company’s clinical research team ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, ... duties on May 15, 2017. , Dr. Terzella completed his residency in Physical ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):